Who Paid My Doc
Hector Correa Colon
Gurabo, PR Medical Doctor
NPI 1487686317 CMS profile 113053
105 Street Santiago North, Gurabo, PR 00778
General payments
$822
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Hector Correa Colon of Gurabo, PR is reported in the CMS Open Payments database as having received $822 across 29 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $52 | 2 | |
| 2024 | General | $39 | 2 | |
| 2023 | General | $140 | 8 | |
| 2022 | General | $144 | 3 | |
| 2021 | General | $65 | 4 | |
| 2020 | General | $128 | 5 | |
| 2019 | General | $255 | 5 |
Beside peers
- Hector Correa Colon
- Puerto Rico median
- Middle half of Puerto Rico
- National median
In program year 2025, general payments to Hector Correa Colon were reported at $52. Among 6,407 Puerto Rico profiles paid that year, the median was $138 and the middle half received between $51 and $379.
Show as a table
| Year | Hector Correa Colon | Puerto Rico median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $255 | $136 | $56–$387 | $163 |
| 2020 | $128 | $80 | $35–$213 | $114 |
| 2021 | $65 | $110 | $37–$313 | $132 |
| 2022 | $144 | $131 | $52–$362 | $149 |
| 2023 | $140 | $127 | $50–$377 | $160 |
| 2024 | $39 | $141 | $56–$375 | $164 |
| 2025 | $52 | $138 | $51–$379 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 104 drugsPart D claims
7,793
Drug cost
$195,111
Branded share of claims
15.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | Brand | 105 | $31,020 | |
| Prednisolone Sodium Phosphate | Generic | 905 | $19,974 | |
| Synthroid Levothyroxine Sodium | Brand | 115 | $11,143 | |
| Eliquis Apixaban | Brand | 16 | $9,612 | |
| Fluocinolone Acetonide Oil | Generic | 123 | $8,561 | |
| Theophylline Er Theophylline Anhydrous | Brand | 133 | $8,500 | |
| Wixela Inhub Fluticasone Propion/Salmeterol | Brand | 48 | $7,874 | |
| Cefprozil | Generic | 330 | $7,348 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 30 | $7,174 | |
| Janumet Sitagliptin Phos/Metformin Hcl | Brand | 12 | $6,050 |
The 10 drugs with the highest cost, of 104 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| SHINGRIX |
|
$14 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
29 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.